Test of Time Points to Durability of Efalizumab Efficacy and Safety


Chicago - The Biologics License Application for efalizumab (Raptiva) for the treatment of moderate-to-severe plaque psoriasis is set to undergo review by the FDA Dermatologic and Ophthalmic Drugs Advisory Committee this month.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.